When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls which genes are expressed, influenced by factors such as diet, exercise, stress, and exposure to pollutants. This means that even if a person has a genetic predisposition to heart disease, their epigenetic profile can reveal whether those genes are actually active or silenced, providing a more dynamic and personalized risk assessment.
The implications of this approach are significant. Traditional risk assessments often rely on static genetic tests or biomarkers like cholesterol levels, which may not capture the full picture. Epigenetic testing can detect early signs of cardiovascular disease before symptoms appear, potentially allowing for earlier intervention. For example, changes in DNA methylation patterns have been linked to atherosclerosis and other heart conditions. By identifying these changes, Cardio Diagnostics hopes to empower individuals and healthcare providers to take preventive measures tailored to the patient’s specific epigenetic profile.
Moreover, the ability to see how lifestyle modifications affect epigenetic marks could motivate behavioral change. If a patient can see that their smoking or poor diet is literally altering their gene expression, they may be more inclined to adopt healthier habits. The company’s platform aims to make this information accessible and actionable, bridging the gap between complex molecular biology and everyday health decisions.
Cardio Diagnostics’ approach also addresses a gap in current cardiovascular care. Many people who have heart attacks have no traditional risk factors, highlighting the need for better screening tools. Epigenetics offers a window into the cumulative effects of environmental exposures and lifestyle over time, which may explain these unexplained events. By integrating epigenetic analysis into routine care, the company hopes to reduce the burden of heart disease, which remains the leading cause of death globally.
As with any emerging technology, there are challenges. Epigenetic testing is still evolving, and large-scale studies are needed to validate its predictive power across diverse populations. Regulatory approval and insurance coverage will also determine how quickly it enters mainstream practice. However, the potential to uncover hidden risks and personalize prevention strategies makes this a promising development in cardiovascular medicine.
For more information on Cardio Diagnostics and its latest updates, visit the company’s newsroom at https://ibn.fm/CDIO. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
